Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL916010 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL589886 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL14134551 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL588927 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL9917631 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL24974550 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL12081887 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL22444953 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL21224008 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL31671113 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025078841-A2 | ANTIBODIES, CONJUGATES, AND USES THEREOF | ANTIKOR BIOPHARMA LIMITED (GB) | 2025-04-17 | — | — | WO | disclosed |
| WO-2025064842-A1 | DIHYDROPHENANTHRENE (DHP) BRIDGED DYES FOR USE IN FLOW CYTOMETRY | BECKMAN COULTER, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20240254567-A1 | DIAMOND MAGNETOMETRY DETECTION OF BIOLOGICAL TARGETS | COLUMBUS NANOWORKS, INC. (US) | 2024-08-01 | — | — | US | disclosed |
| US-11999694-B2 | Delivery of therapeutic alkaloid compounds | SENSORIUM THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240091315-A1 | XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME | AMUNIX PHARMACEUTICALS, INC. | 2024-03-21 | — | — | US | disclosed |
| WO-2024025396-A1 | NOVEL AURISTATIN PRECURSOR DRUG | 주식회사 레고켐 바이오사이언스 | 2024-02-01 | — | — | WO | disclosed |
| US-20230159455-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159455-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159455-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2023076586-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20080318917-A1 | POLYETHYLENE GLYCOLATED SUPEROXIDE DISMUTASE MIMETICS | GALERA THERAPEUTICS, LLC | 2008-12-25 | — | — | US | disclosed |
| US-7432330-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432331-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-20080214439-A1 | AMINO ACID SUBSTITUTED MOLECULES | ALLOZYNE, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080200641-A1 | AMINO ACID SUBSTITUTED MOLECULES | ALLOZYNE, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080096819-A1 | Amino acid substituted molecules | ALLOZYNE, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-7318932-B2 | Coatings for drug delivery devices comprising hydrolitically stable adducts of poly(ethylene-co-vinyl alcohol) and methods for fabricating the same | ADVANCED CARDIOVASCULAR SYSTEMS, INC. (US) | 2008-01-15 | — | — | US | disclosed |
| US-20070166384-A1 | Methods , composition and preparations for delivery of immune response modifiers | 3M INNOVATIVE PROPERTIES COMPANY | 2007-07-19 | — | — | US | disclosed |
| US-7196112-B2 | Cell adhesion inhibitors | BIOGEN IDEC MA INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-20070066533-A1 | Cell adhesion inhibitors | LEE WEN-CHERNG | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318917-A1 | POLYETHYLENE GLYCOLATED SUPEROXIDE DISMUTASE MIMETICS | SOD1, SOD3, CAT | HPGD 122/4885HTT 1383/4885SMN1; SMN2 60/4885 |
| US-20080096819-A1 | Amino acid substituted molecules | BCAT2, DNPEP, PTMS | HPGD 4213/4885HTT 1014/4885SMN1; SMN2 4593/4885 |
| US-20080214439-A1 | AMINO ACID SUBSTITUTED MOLECULES | BCAT2, DNPEP, PTMS | HPGD 4213/4885HTT 1014/4885SMN1; SMN2 4593/4885 |
| US-20070066533-A1 | Cell adhesion inhibitors | VCAM1, EPCAM, ICAM1 | HPGD 3620/4885HTT 3740/4885SMN1; SMN2 4336/4885 |
| US-20230159455-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | PNMT, HNMT, NNMT | HPGD 1080/4885HTT 2860/4885SMN1; SMN2 95/4885 |
| US-20080200641-A1 | AMINO ACID SUBSTITUTED MOLECULES | BCAT2, DNPEP, PTMS | HPGD 4213/4885HTT 1014/4885SMN1; SMN2 4593/4885 |
| US-20070166384-A1 | Methods , composition and preparations for delivery of immune response modifiers | TLR3, MYD88, IFNG | HPGD 660/4885HTT 4298/4885SMN1; SMN2 1625/4885 |
| US-11999694-B2 | Delivery of therapeutic alkaloid compounds | PNMT, HNMT, NNMT | HPGD 1080/4885HTT 2860/4885SMN1; SMN2 95/4885 |
| US-20240091315-A1 | XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME | XPA, TXLNA, NGLY1 | HPGD 2116/4885HTT 525/4885SMN1; SMN2 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.